Streetbeat News

Price Targets

METC

B. Riley Securities analyst Lucas Pipes maintains a Buy rating on Ramaco Resources (NASDAQ:METC) but lowers the price target from $25 to $24.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 2:07 pm

HCC

B. Riley Securities analyst Lucas Pipes maintains a Buy rating on Warrior Met Coal (NYSE:HCC) but lowers the price target from $89 to $87.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 2:04 pm

WFC

Argus Research analyst Stephen Biggar maintains a Buy rating on Wells Fargo (WFC) and raises the price target from $57 to $66.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 2:02 pm

MBUU

Recent analyst ratings for Malibu Boats (NASDAQ:MBUU) show a diverse range of perspectives, with 5 analysts offering ratings in the last three months. The average 12-month price target is $49.4, a 15.91% decline from the prior average, with individual targets ranging from $45.00 to $54.00. Analysts from Keybanc, Raymond James, Truist Securities, B. Riley Securities, and Baird have adjusted their ratings and price targets, reflecting a cautious outlook on the company's performance. Malibu Boats, a leading power boats manufacturer, has seen a significant revenue decline of -37.69% over the past 3 months, with a market capitalization below industry averages, despite strong net margin and ROE.

Portfolio Pulse from Benzinga Insights

April 15, 2024 | 2:02 pm

PNR

Analysts have provided diverse ratings for Pentair (NYSE:PNR), with 14 ratings ranging from bullish to bearish over the last three months. The average 12-month price target for PNR has been raised to $90.64, indicating a 9.2% increase from the previous target of $83.00. Pentair, a global leader in water treatment, reported a revenue of approximately $4.1 billion in 2023 but faced a slight decline in revenue growth by -1.82% as of December 31, 2023. Despite this, the company's financial performance remains strong with a net margin of 21.13%, ROE of 6.65%, and ROA of 3.21%, although it has a higher debt-to-equity ratio of 0.65 compared to industry peers.

Portfolio Pulse from Benzinga Insights

April 15, 2024 | 2:02 pm

BTU

B. Riley Securities analyst Lucas Pipes maintains a Buy rating on Peabody Energy (NYSE:BTU) but lowers the price target from $34 to $32.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 2:02 pm

TDC

Recent analyst ratings for Teradata (NYSE:TDC) show a mix of perspectives, with a total of 8 analysts offering varied views over the past three months. The ratings range from bullish to bearish, with a notable shift towards a somewhat bearish stance in the last 30 days. The 12-month price targets for TDC have seen a downward revision, with the current average target at $50.38, down 11.16% from the previous $56.71. Analysts from firms like Barclays, Citigroup, and Morgan Stanley have adjusted their price targets and ratings, reflecting a cautious outlook on Teradata's financial performance, which includes challenges in revenue growth, net margin, ROE, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

April 15, 2024 | 2:01 pm

CFLT

Confluent (NASDAQ:CFLT) has received diverse analyst ratings over the past quarter, with 18 analysts offering opinions ranging from bullish to bearish. Recent updates show a shift towards more positive ratings, with an average 12-month price target of $33.22, reflecting a 13.5% increase from the previous target of $29.27. Analyst actions include various adjustments to ratings and price targets, indicating changing market dynamics and company performance. Confluent's financials reveal a positive revenue trend with a growth rate of 26.39%, but challenges in net margin, ROE, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

April 15, 2024 | 2:01 pm

APLS

Apellis Pharmaceuticals (NASDAQ:APLS) has received diverse analyst ratings over the past quarter, with a total of 14 analysts offering opinions ranging from bullish to bearish. The recent ratings show a shift towards more positive sentiment in the last 30 days. The 12-month price targets for APLS have an average of $79.43, with a high of $92.00 and a low of $60.00, marking a 13.47% increase from the previous average target of $70.00. Analysts have maintained or raised their ratings and price targets, reflecting changing market dynamics and Apellis Pharmaceuticals' performance. The company, a commercial-stage biopharmaceutical entity, focuses on novel therapies for diseases with high unmet needs. Despite its exceptional revenue growth rate of 545.89% over the past 3 months and a strong net margin of -60.51%, Apellis faces challenges with below-industry-average ROE and ROA, and a prudent debt management strategy with a debt-to-equity ratio of 0.57.

Portfolio Pulse from Benzinga Insights

April 15, 2024 | 2:00 pm

BBW

Build-A-Bear Workshop (NYSE:BBW) received mixed ratings from 4 analysts, with a shift towards bullish sentiment in the last 30 days. The average 12-month price target is $40.75, slightly up from $40.67. The company's financial performance shows positive revenue growth, exceptional net margin, and strong ROE and ROA, with a prudent debt management strategy. Analysts maintain or adjust their ratings based on company performance and market conditions.

Portfolio Pulse from Benzinga Insights

April 15, 2024 | 2:00 pm